Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomised, Double-blind, Parallel and Placebo-controlled Trial Investigating Safety and Efficacy of LIB-01 in Treatment of Erectile Dysfunction

Next Previous
Trial Profile

A Phase 2a, Randomised, Double-blind, Parallel and Placebo-controlled Trial Investigating Safety and Efficacy of LIB-01 in Treatment of Erectile Dysfunction

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LIB 01 (Primary)
  • Indications Erectile dysfunction; Premature ejaculation
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Dicot

Most Recent Events

  • 01 Jul 2025 Planned End Date changed from 30 Jun 2025 to 30 Aug 2025.
  • 01 Jul 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Jul 2025.
  • 25 Jun 2025 According to a Dicot media release, recruitment has been completed and that all participants have been dosed. The company can thus conclude that the clinical study will be completed in August. The results are reported no later than three months thereafter. After completion of the study, control of the collected data, locking of the database and subsequent statistical analysis before results can be reported, a work that is estimated to take two to three months.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top